Salix Pharmaceuticals Return on Equity:
12.25% for Dec. 31, 2012Salix Pharmaceuticals Historical Return on Equity Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | 12.25% |
| Sept. 30, 2012 | 15.78% |
| June 30, 2012 | 20.00% |
| March 31, 2012 | 20.64% |
| Dec. 31, 2011 | 19.18% |
| Sept. 30, 2011 | 18.64% |
| June 30, 2011 | 10.38% |
| March 31, 2011 | -0.41% |
| Dec. 31, 2010 | -7.26% |
| Sept. 30, 2010 | -17.22% |
| June 30, 2010 | -20.11% |
| March 31, 2010 | -18.87% |
| Dec. 31, 2009 | -15.97% |
| Sept. 30, 2009 | -18.99% |
| June 30, 2009 | -17.87% |
| March 31, 2009 | -14.33% |
| Dec. 31, 2008 | -17.62% |
| Sept. 30, 2008 | -19.92% |
| June 30, 2008 | -12.59% |
| March 31, 2008 | Go Pro |
| Dec. 31, 2007 | Go Pro |
| Sept. 30, 2007 | Go Pro |
| June 30, 2007 | Go Pro |
| March 31, 2007 | Go Pro |
| Dec. 31, 2006 | Go Pro |
| Sept. 30, 2006 | Go Pro |
| June 30, 2006 | Go Pro |
| March 31, 2006 | Go Pro |
| Dec. 31, 2005 | Go Pro |
| Sept. 30, 2005 | Go Pro |
| June 30, 2005 | Go Pro |
| March 31, 2005 | Go Pro |
| Dec. 31, 2004 | Go Pro |
| Sept. 30, 2004 | Go Pro |
| June 30, 2004 | Go Pro |
| March 31, 2004 | Go Pro |
| Dec. 31, 2003 | Go Pro |
| Sept. 30, 2003 | Go Pro |
| June 30, 2003 | Go Pro |
| March 31, 2003 | Go Pro |
| Dec. 31, 2002 | Go Pro |
| Sept. 30, 2002 | Go Pro |
| June 30, 2002 | Go Pro |
| March 31, 2002 | Go Pro |
| Dec. 31, 2001 | Go Pro |
| Sept. 30, 2001 | Go Pro |
| June 30, 2001 | Go Pro |
| March 31, 2001 | Go Pro |
About Return on Equity (ROE)
Return on equity (ROE) measures the rate of return on the money invested by common stock owners and retained by the company thanks to previous profitable years. It demonstrates a company's ability to generate profits from shareholders' equity (also known as net assets or assets minus liabilities).
ROE shows how well a company uses investment funds to generate growth. Return on equity is useful for comparing the profitability of companies within a sector or industry.
Investors generally are interested in company's that have high, increasing returns on equity.
Learn More
SLXP Return on Equity Benchmarks
| Companies | |
|---|---|
| Catalyst Pharmaceutical Partners | -55.23% |
| Valeant Pharmaceuticals International | -3.46% |
| Auxilium Pharmaceuticals | 54.31% |
SLXP Return on Equity Rankings
| Overall |
80th percentile 1491 of 7590 |
| Sector |
80th percentile 129 of 651 in Healthcare |
| Industry |
80th percentile 13 of 65 in Drug Manufacturers - Specialty & Generic |
SLXP Return on Equity Range, Past 5 Years
| Minimum | -20.11% | Jun 2010 |
| Maximum | 20.64% | Mar 2012 |
| Average | -3.38% |
SLXP News
Salix Pharmaceuticals Outlines Data Presentations at Digestive Disease Week 2013
Business Wire May 17
Business Wire May 17
